The V Foundation for Cancer Research Chicago Epicurean Raises Over $1.13 Million for Cancer Research
Read moreState: North Carolina
Gerard C. Blobe, M.D., Ph.D.
Angelique Whitehurst, Ph.D.
Funded by the Jimmy V Celebrity Golf Classic Volunteer Grant
In honor of Mike Howard
Ian J. Davis, M.D., Ph.D.
Abeloff V Scholar*
Gang (Greg) Wang, Ph.D.
Abeloff V Scholar*
Enzymes that modify chromatin (the physiological form of DNA) are often found abnormally expressed, mutated, and/or hyper-activated among various forms of blood malignancies. Somatic mutations of EZH2, a gene that encodes a critical chromatin-modulating enzyme, are responsible for over 10-20% of clinically diagnosed diffused large B-cell lymphomas and follicular lymphoma. These mutations are known to lead to EZH2 hyperactivity in cancer cells. However, it is largely unclear how EZH2 is associated with chromatin, which is critical for EZH2’s role in gene control and cancer promotion. Using the biochemical approach as a discovery tool, we demonstrate that the activities of EZH2 rely on a critical interacting factor PHF19 or PHF1, which opens a possibility for pharmacological manipulation and makes them ideal drug targets. Abnormalities of both PHF1 and PHF19 have been frequently found in human cancers including lymphoma patients, which resonate well with their roles in regulating EZH2 during cancer development. Future investigation shall be performed to design new ways for targeting EZH2’s cofactors as novel anti-cancer interventions.
Kris C. Wood, Ph.D.
2013 V Foundation Wine Celebration
Volunteer Grant in Honor of
John and Anne Sachs
Michael J. Emanuele, Ph.D.
Chad V. Pecot, M.D.
Cancer is a leading cause of death in the U.S. and the world, largely due to our inability to block the spread of disease (termed metastases). However, over the past several years the roles of recently discovered genes, called microRNAs, have been shown to play vital roles in controlling cancer growth and metastases. One group of these microRNAs, called the miR-200 family, has shown particular promise by blocking many critical functions known to drive cancer. Recently, we discovered that the miR-200 family could block the formation of new blood vessels inside tumors, which resulted in decreased metastases. Our proposal focuses on understanding how miR-200 blocks formation of blood vessels in cancer, and further explores the use of miR-200 delivery as a new therapeutic option to treat cancer.
Peter S. Turk, M.D.
Funded by Papa John’s International, Inc.
Tian Zhang, M.D.
Funded by friends of TK and Virginia Wetherell
Metastatic castration resistant prostate cancer (mCRPC) – prostate cancer which is resistant to androgen deprivation therapy – can be often aggressive and lethal. The androgen receptor (AR) has an important role in the disease course of prostate cancer, since both enzalutamide and abiraterone acetate improve overall survival by exerting effects on the AR pathway. Our preclinical data shows that AR can increase proteins that are needed maintaining copper balance, such as the copper transporter protein, which we found in prostate cancer samples. To take advantage of the copper biology in prostate cancer, we performed a “conditional lethal” screen for drugs that exert their cancer-killing effects based on the presence of copper. This screen identified disulfiram “Antabuse”, as a potential drug for prostate cancer. Antabuse has been tested before in prostate cancer but never in the presence of copper. Mouse models of prostate cancer have shown that those cancer masses can shrink when Antabuse is given along with copper. Therefore, we propose to study the combination of Antabuse and intravenous copper, to find the safety profile for this combination of drugs. In addition, we will study the copper uptake of these patients’ prostate cancers using a radiolabeled copper PET scan. These studies will allow us to see whether the baseline copper uptake of a patient’s prostate cancer is linked to their response on the combination of Antabuse and intravenous copper.
